Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer Presented ByDr Yara Verschoor, Netherlands Cancer Institute, the Netherlands TrialPhase 2, NICHE-3 ConferenceESMO 2023 18 December, 2023 16:04